Theravance Reports Second Quarter 2012 Financial Results – MarketWatch (press release)

Theravance Reports Second Quarter 2012 Financial Results
MarketWatch (press release)
In July 2012, GSK and Theravance announced the submission of regulatory applications for FF/VI (100/25mcg) in both the EU and the US for patients with COPD and for FF/VI (100/25mcg and 200/25mcg) in the EU for patients with asthma. GSK and A replay

and more »

View full post on world asthma day – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *